Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 7—July 2022

Analyzing and Modeling the Spread of SARS-CoV-2 Omicron Lineages BA.1 and BA.2, France, September 2021–February 2022

Mircea T. Sofonea, Bénédicte Roquebert, Vincent Foulongne, David Morquin, Laura Verdurme, Sabine Trombert-Paolantoni, Mathilde Roussel, Jean-Christophe Bonetti, Judith Zerah, Stéphanie Haim-Boukobza, and Samuel AlizonComments to Author 
Author affiliations: Université de Montpellier, Montpellier, France (M.T. Sofonea); Laboratoire Cerba, Saint Ouen L’Aumône, France (B. Roquebert, L. Verdurme, S. Trombert-Paolantoni, M. Roussel, S. Haim-Boukobza); Centre Hospitalier Universitaire de Montpellier, Montpellier (V. Foulongne, D. Morquin); Laboratoire Cerballiance Paris et Île-de-France Est, Paris, France (J.-C. Bonetti, J. Zerah); Centre National de la Recherche Scientifique, Paris (S. Alizon)

Main Article

Table 2

Results of ID Solution Revolution SARS-CoV-2 variant-specific screening tests (N = 193,256), France, December 18, 2021–February 28, 2022*

Characteristic Value
Age of patient, y, median (95% CI)
36 (6–74)
General population 187,292 (96.9)
5,964 (3.1)
Ile-de-France 40,185 (20.8)
Hauts-de-France 26,382 (13.7)
Normandie 31,205 (16.2)
Nouvelle-Aquitaine 13,236 (6.9)
Provence-Alpes-Côte d’Azur 31,299 (16.2)
Occitanie 9,034 (4.7)
Corse 8,031 (4.2)
Bourgogne-Franche-Comté 4,366 (2.3)
Grand Est 6,865 (3.6)
Centre-Val de Loire 10,412 (5.4)
Bretagne 9,405 (4.9)
2,836 (1.5)
A0B9C1D0 12,955 (6.7)
A0B9C0D1 154,134 (79.8)
A0B9C1D1 173 (0.1)
A1B9C0D0 4,762 (2.5)
Other 21,232 (10.9)

*Values are no. (%) patients except as indicated.

Main Article

Page created: May 03, 2022
Page updated: June 18, 2022
Page reviewed: June 18, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.